anonymous
Guest
anonymous
Guest
Are I talking about Michelle?Please get rid of the MSL in California. She was a terrible rep before this job and Is driving our office nuts in this new job. She was annoying before and is worse now.
Are I talking about Michelle?Please get rid of the MSL in California. She was a terrible rep before this job and Is driving our office nuts in this new job. She was annoying before and is worse now.
Please get rid of the MSL in California. She was a terrible rep before this job and Is driving our office nuts in this new job. She was annoying before and is worse now.
Not true! This one is a winner.AA running another into the ground.
Haha. Take a look at your stock.Not true! This one is a winner.
Anyone who hired MM as an MSL is nuts. Lack of social awareness and fails miserably at speaking to providers. The drug is going to be a bust. Don’t do it!
Heck yeah. Please get her out of our offices. Bad rep. Worse MSL. No people skillsAre I talking about Michelle?
LOL - Best reference of our device so far. Maybe we should look into the military applications. Certainly new device but not needed or desired in this crowded market space. Riding this gig until a better opportunity comes along, hopefully soon. Pressure will definitely be on in 2022.Device doesn’t work. Doctor said his patient felt like they were water-boarded
Device doesn’t work. Doctor said his patient felt like they were water-boarded
You clearly do not work here. Far from a dumpster fire. Sorry you didn’t get the position. Maybe if you would spend more time working and not posting fake news on this website, you would have gotten the position.
Q1 goals = laughable.I do work here and now nervous that we were down trx and nrx last week. Rigo said we needed to be at 4000 for q4. We are no where near that. So agree not a dumpster fire but not smooth sailing at all.
Still in "Sell the News" mode apparently. Wall Street must see the same Rx data we see - no traction and declining. Stock was at a high of 34.75 in August and then inept managers were hired. Stock is now below $9 (8.79) with no hopes of recovering.Oh shut up and grow a pair. This almost always happens with an FDA approval. You ever hear of ‘sell the news’?
Impel will NOT make it.So unmotivated after mixed messages from my manager. “I don’t want to make call reporting the focus but we need to show activity to the higher ups.” Micromanaging call activity in a covid world for a product nobody wants. Ugh!